Long-Acting Injectable PrEP
Welcome to the Long-Acting Injectable (LAI) page of NASTAD’s PrEP Access Microsite! This page includes implementation information for both formulations of long-acting injectable PrEP, cabotegravir (Apretude) and lenacapavir (Yeztugo), including frequently asked questions, dosing schedule infographics, webinar recordings, and partner resources. For questions about long-acting injectable PrEP, please contact NASTAD’s PrEP Access team at PrEP@NASTAD.org.
Long-Acting Injectable PrEP Implementation Resources
On June 18, 2025, the U.S Food and Drug Administration approved Yeztugo (lenacapavir) for PrEP, making it the second long-acting injectable treatment option available for the primary prevention of HIV. Both Yeztugo and Apretude are indicated for adults and adolescents weighing at least 77 pounds who are at risk of sexually acquiring HIV.
The addition of lenacapavir to the biomedical intervention tool box is exciting, as it provides the longest-acting form of any PrEP modality yet and serves as an additional option for people vulnerable to HIV transmission, preferring an injectable product requiring infrequent administration. Long-acting injectable PrEP creates new opportunities to support individuals in maintaining adherence, preventing or alleviating pill fatigue, and reducing stigma or privacy concerns associated with taking oral medications. Adolescents, people who use drugs, individuals experiencing homelessness, and others who experience challenges taking daily oral PrEP could benefit from these LAI PrEP modalities.
Frequently Asked Questions for Implementation
- Long-Acting Injectable Cabotegravir (Apretude)
- Lenacapavir (Yeztugo)- Coming soon
Long-Acting Injectable Cabotegravir Dosing
This infographic walks through the initiation and dosing schedule for Apretude® to assist HIV prevention programs in implementing long-acting injectable PrEP.
Long-Acting Injectable PrEP: Partner Resources
- AVAC
- Injectable Cabotegravir for PrEP
- BLUPrInt Cabotegravir Long Acting Resources
- California PTC Long-Acting Injectable PrEP
- New York Knows- Long-Acting Injectable PrEP Learning Collaborative - University of Rochester
- O’Neill Institute- Brief: Effective Implementation of Longer-Acting HIV Treatment and PrEP Requires Delivery System Innovation
- LEAP—Long-Acting/ Extended Release Antiretroviral Research Resource Program
Clinical Guidelines:
Jurisdiction Examples: